RA Capital Management and Khosla Ventures led an $85m Series A round in Stylus Medicine.

RA Capital Management, a multi-stage investment manager, and Khosla Ventures, a venture capital firm, led an $85m Series A round in Stylus Medicine, a Cambridge-based biotechnology company, with the participation from Chugai Venture Fund, Eli Lilly and Company, and Johnson & Johnson Innovation. “Stylus was created in 2022 by Raven, RA Capital’s healthcare incubator, and Khosla Ventures to solve the fundamental challenges holding back genetic medicines,” Joshua Resnick, M.D., RA Capital Partner and President of Raven.